ABO Blood Group and Inhibitor Risk in Severe Hemophilia A Patients : A Study from the Italian Association of Hemophilia Centers
Thieme. All rights reserved..
Considering the profound influence exerted by the ABO blood group system on hemostasis, mainly through the von Willebrand factor and factor VIII (FVIII) complex, we have conducted a study evaluating the possible role of blood type on the risk of inhibitor development in hemophilia A. A total of 287 consecutive Caucasian patients with severe hemophilia A (202 without FVIII inhibitors and 85 with FVIII inhibitors) followed at seven Italian Hemophilia Treatment Centers belonging to the Italian Association of Hemophilia Centers (AICE) were included in the study. A higher prevalence of O blood group was detected in patients without inhibitors as compared in inhibitor patients (55 vs. 30.6%; p < 0.001). Among the other variables analyzed (age, F8 mutation, type and intensity of treatment and treatment regimen), F8 mutation class (high-risk vs. low-risk), and treatment regimen (on-demand vs. prophylaxis) were significantly correlated with inhibitor development. However, on a multivariate analysis, only the effects of F8 mutation and ABO blood type were independent of other covariates, being that non-O blood type is associated with a 2.89-fold increased risk of inhibitor development. In conclusion, our study supports the protective effect of O blood type on inhibitor risk in severely affected hemophilia A patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:47 |
|---|---|
| Enthalten in: |
Seminars in thrombosis and hemostasis - 47(2021), 1 vom: 29. Feb., Seite 84-89 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Franchini, Massimo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 30.08.2021 Date Revised 30.08.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1055/s-0040-1718870 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320861465 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320861465 | ||
| 003 | DE-627 | ||
| 005 | 20231225174547.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1055/s-0040-1718870 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1069.xml |
| 035 | |a (DE-627)NLM320861465 | ||
| 035 | |a (NLM)33525041 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Franchini, Massimo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a ABO Blood Group and Inhibitor Risk in Severe Hemophilia A Patients |b A Study from the Italian Association of Hemophilia Centers |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.08.2021 | ||
| 500 | |a Date Revised 30.08.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Thieme. All rights reserved. | ||
| 520 | |a Considering the profound influence exerted by the ABO blood group system on hemostasis, mainly through the von Willebrand factor and factor VIII (FVIII) complex, we have conducted a study evaluating the possible role of blood type on the risk of inhibitor development in hemophilia A. A total of 287 consecutive Caucasian patients with severe hemophilia A (202 without FVIII inhibitors and 85 with FVIII inhibitors) followed at seven Italian Hemophilia Treatment Centers belonging to the Italian Association of Hemophilia Centers (AICE) were included in the study. A higher prevalence of O blood group was detected in patients without inhibitors as compared in inhibitor patients (55 vs. 30.6%; p < 0.001). Among the other variables analyzed (age, F8 mutation, type and intensity of treatment and treatment regimen), F8 mutation class (high-risk vs. low-risk), and treatment regimen (on-demand vs. prophylaxis) were significantly correlated with inhibitor development. However, on a multivariate analysis, only the effects of F8 mutation and ABO blood type were independent of other covariates, being that non-O blood type is associated with a 2.89-fold increased risk of inhibitor development. In conclusion, our study supports the protective effect of O blood type on inhibitor risk in severely affected hemophilia A patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a ABO Blood-Group System |2 NLM | |
| 700 | 1 | |a Coppola, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Santoro, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a De Cristofaro, Raimondo |e verfasserin |4 aut | |
| 700 | 1 | |a Barillari, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Giordano, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Gresele, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Lassandro, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Napolitano, Mariasanta |e verfasserin |4 aut | |
| 700 | 1 | |a Lucchini, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Luciani, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Ferretti, Antonietta |e verfasserin |4 aut | |
| 700 | 1 | |a Baldacci, Erminia |e verfasserin |4 aut | |
| 700 | 1 | |a Riccardi, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Santoro, Rita Carlotta |e verfasserin |4 aut | |
| 700 | 1 | |a Pasca, Samantha |e verfasserin |4 aut | |
| 700 | 1 | |a Zanon, Ezio |e verfasserin |4 aut | |
| 700 | 1 | |a Tagliaferri, Annarita |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Seminars in thrombosis and hemostasis |d 1975 |g 47(2021), 1 vom: 29. Feb., Seite 84-89 |w (DE-627)NLM000434361 |x 1098-9064 |7 nnns |
| 773 | 1 | 8 | |g volume:47 |g year:2021 |g number:1 |g day:29 |g month:02 |g pages:84-89 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1055/s-0040-1718870 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 47 |j 2021 |e 1 |b 29 |c 02 |h 84-89 | ||